WallStSmart
JANX

Janux Therapeutics Inc

NASDAQ: JANX · HEALTHCARE · BIOTECHNOLOGY

$14.23
-2.91% today

Updated 2026-06-05

Market cap
$826.95M
P/E ratio
P/S ratio
60.22x
EPS (TTM)
$-1.84
Dividend yield
52W range
$12 – $35
Volume
1.0M

Janux Therapeutics Inc (JANX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$0.00$380000.00$3.64M$8.61M$8.08M$10.59M$10.00M
Revenue growth (YoY)+857.1%+136.8%-6.1%+31.0%-5.6%
Cost of revenue$6000.00$13000.00$36.57M$75.70M$1.96M$2.06M$2.03M
Gross profit$-6000.00$-13000.00$3.64M$8.61M$6.13M$8.53M$7.97M
Gross margin-3.4%100.0%100.0%75.8%80.5%79.7%
R&D$3.00M$3.04M$26.24M$53.44M$54.92M$68.39M$125.90M
SG&A$772000.00$1.80M$10.33M$22.26M$26.14M$41.05M$41.77M
Operating income$-3.77M$-4.84M$-32.93M$-67.09M$-72.98M$-98.85M$-157.67M
Operating margin-1274.5%-905.4%-779.0%-902.9%-933.6%-1576.7%
EBITDA$-3.77M$-6.57M$-32.82M$-66.25M$-71.02M$-96.79M$-111.60M
EBITDA margin-1727.6%-902.3%-769.3%-878.7%-914.1%-1116.0%
EBIT$-3.77M$-6.58M$-32.93M$-67.09M$-72.98M$-98.85M$-113.63M
Interest expense$233000.00$206000.00$370000.00$4.03M
Income tax$233000.00$-1.53M$-113000.00$-8.90M$1.79M
Effective tax rate-5.8%18.4%0.3%14.1%-3.2%0.0%0.0%
Net income$-4.24M$-6.78M$-32.56M$-54.15M$-58.29M$-68.99M$-113.63M
Net income growth (YoY)-60.1%-379.9%-66.3%-7.6%-18.4%-64.7%
Profit margin-1785.3%-895.2%-628.8%-721.2%-651.6%-1136.3%

Frequently asked questions

What is Janux Therapeutics Inc's revenue?

Janux Therapeutics Inc's trailing twelve-month revenue is $13.73M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is JANX?

In its most recent fiscal year, JANX ran a gross margin of 79.71%, an operating margin of -1,576.67%, and a net margin of -1,136.25%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does JANX generate?

JANX produced $-83.28M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is JANX's balance sheet healthy?

JANX holds $52.33M in cash and equivalents against — in long-term debt, on $956.82M of shareholder equity. That debt is best read against the cash flow the business throws off each year.